🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07539675
Recruiting Observational

The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis

NCT07539675 · tracked via the Priya Life Science China tracker
Sponsor
Zhongnan Hospital
Phase
Observational
Started
2025-10-01
Last updated
2026-04-20

Condition(s) studied

Primary Angle-Closure Glaucoma

Investigational drug(s) / intervention(s)

No Additional Experimental Intervention

No Additional Experimental Intervention: No Additional Experimental Intervention

Study summary

Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.

Eligibility

Sex
ALL
Min age
50 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Clinically diagnosed with primary angle-closure glaucoma (PACG) * Aged ≥ 50 years, no gender restriction * Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity * Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology * Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery Exclusion Criteria: * Secondary glaucoma * History of previous intraocular surgery * Systemic diseases that can cause abnormal ocular zonules * Other severe ocular diseases * Long-term use of medications affecting connective tissue metabolism

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhongnan Hospital of Wuhan University Wuhan Hubei Recruiting

More Zhongnan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07539675 on ClinicalTrials.gov ↗ ← All trials in China